Epratuzumab, designated as hLL 2, is a humanized IgG1 monoclonal antibody targeting CD22, a cell surface antigen expressed predominantly on B cells. This antibody functions not only as an immunomodulatory agent but also as a tumor-imaging agent due to its specific binding to CD22. Epratuzumab has demonstrated the ability to induce phosphorylation of CD22, which plays a critical role in the modulation of B cell signaling and function. The primary applications of Epratuzumab have been in the study of non-Hodgkin?€?s lymphomas (NHL) and various autoimmune diseases, where it has shown potential in modulating immune responses and providing diagnostic imaging insights.
Epratuzumab, designated as hLL 2, is a humanized IgG1 monoclonal antibody targeting CD22, a cell surface antigen expressed predominantly on B cells. This antibody functions not only as an immunomodulatory agent but also as a tumor-imaging agent due to its specific binding to CD22. Epratuzumab has demonstrated the ability to induce phosphorylation of CD22, which plays a critical role in the modulation of B cell signaling and function. The primary applications of Epratuzumab have been in the study of non-Hodgkin?€?s lymphomas (NHL) and various autoimmune diseases, where it has shown potential in modulating immune responses and providing diagnostic imaging insights.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
